Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Completed study drug treatment in parent study (VX18-445-106 Part B, NCT03691779), or had study drug interruption(s) in parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study~Key Exclusion Criteria:~* History of study drug intolerance in parent study~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triple Combination Arm (Type: EXPERIMENTAL): Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.

Based on this trial design, predict the completion outcome and termination type (if applicable).